Dollars for Profs
Dig Into University Researchers' Outside Income and Conflicts of Interest
Published Dec. 6, 2019
This database was last updated in December 2019 and should only be used as a historical snapshot. There may be new or amended records not reflected here.
Conflict of Interest
Institutions must file significant disclosures to the National Institutes of Health if they determine financial relationships could affect the design, conduct or reporting of the NIH-funded research. The NIH provided us with their entire financial conflict of interest database, with filings from 2012 through 2019.
Should you be removed from our database? Contact us at [email protected]. Read more below.
Michael Brenner
Georgetown University, Department: Internal Medicine/medicine
Should you be removed from our database? Contact us at [email protected]. Read more below.
Synovex
Equity Interest - Non-publicly traded entity ( e.g., stock, stock option, or other ownership interest)
The Co-Chairs of the Partners HealthCare Committee on Conflict of Interest (CCOI), by delegation, evaluated Dr. Brenner’s financial interest in Synovex, a private biotech company that has developed highly specific cadherin-11 antagonists for the treatment of rheumatoid arthritis and fibrotic diseases. The research under this R01 grant is aimed at determining the molecular mechanism by which cadherin-11 stimulates cell signaling and proliferation. The research will use cadherin-11 fusion proteins, RNAi and mAb. Synovex is developing an anti-cadherin-11 mAb biotherapeutic, which could be considered a “similar compound” to some of the stimulating or blocking reagents against cadherin-11 used in this R01 research. Upon review, the Co-Chairs determined that Synovex could be affected by the research in that new discoveries about cadherin-11 could affect the company’s research program. That is, this SFI was determined to be a related SFI. The Co-Chairs further determined that, given the magnitude and nature of the SFI, the interest creates an FCOI with this R01 grant; that is, the interest could directly and significantly affect the design, conduct, or reporting of the research.
Cadherin11 in cancer & rheumatoid arthritis: Common target, common therapies? (5)
Basal-like breast cancers and brain tumors of the glioblastoma type are among the poorest prognosis cancers with no effective treatments. This proposal links a molecular pathway elevated in these tumors to a similar pathway important in the inflammatory disease rheumatoid arthritis. We propose that drugs currently in use for arthritis as well as drugs repurposed to inhibit the common pathway will be useful as novel cancer therapies.
Filed on April 17, 2014.
Tell us what you know about Michael Brenner's disclosure
We're still reporting about conflicts of interest. Is there something you'd like to tell us about this disclosure?
Other search results for: “Michael Brenner”
| Name | Institution | Type | Company | Disclosed Value |
|---|---|---|---|---|
| Michael Brenner | Brigham and Women's Hospital | Conflict of Interest | Adheron Therapeutics | Value cannot be readily determined |
| Michael Brenner | Georgetown University | Conflict of Interest | Synovex | $20,000 - $39,999 |
| Michael Brenner | Brigham and Women's Hospital | Conflict of Interest | Adheron Therapeutics | $40,000 - $59,999 |
Notes: When a more specific filing date is not available for an individual financial disclosure or conflict of interest form, we use the year the form was filed. If the year was not disclosed, we report the range of years covered by our public records requests. In a few cases, a start date was provided instead of a filing date. In those cases, we use the start date instead.
Fewer than 10% of records from the University of Florida and fewer than 1% of records from the University of Texas system were removed because they did not contain enough information.
ProPublica obtained additional financial disclosures and conflict of interest forms that we have not yet digitized and added to the database. You can download those disclosures in the ProPublica Data Store.